Taysha Gene Therapies (TSHA) Q3 2024 earnings summary

Executive summary

• TSHA-102 gene therapy for Rett syndrome advanced with ongoing Phase 1/2 REVEAL trials in adolescent/adult and pediatric patients, showing favorable safety and early, sustained clinical improvements.

• Regulatory progress includes FDA RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, with pivotal product approval and positive FDA interactions on trial design and endpoints.

• All other programs, including TSHA-120 for GAN, were discontinued or deprioritized to focus resources on Rett syndrome.

• Strong patient and caregiver demand for trial participation, with multiple sites active and broad interest in the program.

• Clinical data from both dose cohorts in REVEAL trials expected in the first half of 2025.

Financial highlights

• Research and development expenses increased to $50.7M for the nine months ended September 30, 2024, up from $44.1M year-over-year, mainly due to GMP batch activities and higher R&D headcount.

• General and administrative expenses decreased to $22.3M from $23.3M year-over-year, primarily due to lower warrant-related costs.

• Net loss for Q3 2024 was $25.5M ($0.10 per share), a significant improvement from $117.1M ($0.93 per share) in Q3 2023, and net loss for the nine months ended September 30, 2024 was $70.5M, down from $159.3M in the prior year period.

• Cash and cash equivalents totaled $157.7M as of September 30, 2024, expected to fund operations into Q4 2026.

• Non-cash impairment charge of $4.8M recorded for manufacturing facility and assets held for sale.

Outlook and guidance

• Longer-term safety and efficacy data from both high- and low-dose REVEAL trial cohorts anticipated in H1 2025.

• Ongoing FDA discussions to finalize registrational study design and endpoints, with alignment targeted for H1 2025.

• Current cash runway supports planned operations and capital requirements into Q4 2026, but additional capital may be needed for future development and commercialization.